AVE
Avecho Biotechnology Limited
🇦🇺 ASX
📈 HIGH PRICE GROWTH
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
+ 20.00%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
8
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The firm's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The firm is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
📈 Performance
Price History
-90.04%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
44
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
37
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AVE
8
📊 Total Capital Earnings
$6K
🔃 Average investment frequency
58 weeks
💵 Average investment amount
$454
⏰ Last time a customer invested in AVE
9 days
AVE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
13%
100k - 150k
25%
50k - 100k
13%
Less than 50k
50%
👶 Age of investors
18 - 25
26 - 34
25%
35 - 90
75%
🙋 Legal gender of investors
Female
38%
Male
63%
Pearlers who invest in AVE also invest in...
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
17.84%
📊 Share price
$63.14 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.21%
📊 Share price
$102.85 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
22.44%
📊 Share price
$50.57 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
🤖 TECHNOLOGY
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. The company has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
🙌 Performance (5Yr p.a)
-18.88%
📊 Share price
$0.49 AUD
📦 LOGISTICS
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. Its principal activities include the cultivation of medicinal cannabis, procurement of raw materials and production of medicinal cannabis medicines; the supply of medicinal cannabis products into Australia and Europe; the supply of medicinal cannabis products for observational and clinical studies and research and development of new medicinal cannabis products, and the development of a psychedelics business including sponsoring a clinical trial into the treatment of refractory depression with psilocybin assisted therapy, construction of a psilocybin mushroom cultivation facility, and establishment of a psychedelic treatment clinic. The company has two global production sites for the manufacture of its own-branded and white-label ranges medicinal cannabis products.
🙌 Performance (5Yr p.a)
-13.17%
📊 Share price
$0.14 AUD
📦 LOGISTICS
Want more shares? Try these...
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its drug delivery system Tocopherol Phosphate Mixture (TPM). The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, Daptomycin, Propofol and Veterinary Applications. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Company’s Human Health segment covers delivery of pharmaceutical products through gels, injectables and patches. This segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. The firm is also developing TPM to enhance feed efficiency and health of livestock. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
🕊️
Social Score
41
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.